A Single-center, Non-randomized, Open-label Study to Assess the Pharmacokinetics of Aleglitazar (RO0728804) After Administration of Single and Multiple Oral Doses of 150mcg Tablet in Healthy Chinese Subjects
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2016
At a glance
- Drugs Aleglitazar (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Roche
- 14 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jan 2013 Planned End Date changed from 1 Sep 2013 to 1 Oct 2013 as reported by ClinicalTrials.gov.
- 03 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.